Constellation Pharmaceuticals will give a presentation on EZH2 and exhibit posters on EZH2 and BET at the AACR Annual Meeting, April 5-9 in San Diego, CA.
At this year’s AACR Annual Meeting Constellation will be represented by one oral presentation and four posters encompassing work on chromatin biology.
Patrick Trojer will be giving a talk entitled “Targeting Histone Lysine Methylation in Cancer”, in Saturday’s 11:45 am session, room 28 A-C.
In addition, the following posters will be presented:
Defining the determinants of sensitivity and resistance to BET bromodomain inhibition http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=bcdd91b7-1a6c-4319-b2a1-64949b8befe8&cKey=8d6b912a-f64c-4c0d-90fc-374fc3efebb5&mKey=%7b6FFE1446-A164-476A-92E7-C26446874D93%7d
Synergistic anti-tumor activity of lenalidomide with the BET bromodomain inhibitor CP1203 in bortezomib-resistant mantle cell lymphoma http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3404&sKey=0cb37109-a692-43e9-9dc0-b7294f27554a&cKey=61214dcb-4bc2-4e08-93ec-ec118dd82a72&mKey=6ffe1446-a164-476a-92e7-c26446874d93
Inhibition of the histone methyl transferase EZH2 causes viability defects in multiple myeloma http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3404&sKey=744c7102-2c4a-4fd6-87cf-6590b6e790b3&cKey=9cad05b6-ec2b-489f-8356-794d99f51dbe&mKey=6ffe1446-a164-476a-92e7-c26446874d93
CPI-169, a novel and potent EZH2 inhibitor, synergizes with CHOP in vivo and achieves complete regression in lymphoma xenograft models